Tirzepatid

GLP-1 Drugs: Could ‘Weight Loss Injections’ Treat Multiple Addictions?

by

The burgeoning use of GLP-1 receptor agonists – initially developed to treat type 2 diabetes and obesity – is now attracting attention for a surprising potential benefit: reducing the risk of substance use disorders. Emerging research suggests these medications, including drugs like Ozempic and Mounjaro, may dampen cravings and reduce the likelihood of both fresh … Read more

Novo Nordisk’s CagriSema Fails to Meet Goals vs. Eli Lilly’s Tirzepatid – Stock Drops

by

Berlin – Shares in Novo Nordisk experienced a significant downturn on Monday, February 23, 2026, following the release of Phase 3 trial data for its investigational weight-loss drug, CagriSema. The data revealed that CagriSema did not demonstrate superiority to Eli Lilly’s tirzepatide, currently marketed as Mounjaro and Zepbound, in terms of weight loss. This setback … Read more